October 29, 2014
BOSTON-BASED COMPANY PROVIDES EPIDEMIOLOGICAL AND ANALYTIC EXPERTISE TO FEDERAL, COMMERCIAL AND INTERNATIONAL CLIENTS
McLean, VA — Booz Allen Hamilton today announced that it has acquired Boston, MA.-based Epidemico, Inc., a move that underscores the firm’s commitment to further develop leading edge analytic capabilities in critical areas such as population health.
Epidemico is an informatics company providing early insights, continuous monitoring and consumer engagement for varied aspects of population health, including disease outbreaks, drug safety, supply chain vulnerabilities and more. By combining innovative data acquisition and analysis technologies with public health expertise, Epidemico delivers sophisticated surveillance systems and consumer-centric engagement tools.
“The acquisition of Epidemico aligns closely with our Vision 2020 long-term growth strategy, expanding our client offerings with some truly leading capabilities and products that will drive growth opportunities,” said Booz Allen President and Chief Operating Officer Horacio Rozanski. “The addition of Epidemico’s analytic capabilities to our data science team builds on the firm’s broader strategy of expanding its engineering and technology expertise to respond to the changing demands of government and commercial clients seeking more cost-effective and innovative solutions.”
Epidemico, with a staff of industry recognized epidemiologists and health leaders, is known for pioneering global population health solutions that radically disrupt traditional detection, reporting and engagement systems. For example, one of Epidemico’s commercially licensed products, HealthMap, leads the field in digital disease detection tracking over 200 infectious diseases worldwide in 15 different languages.
Epidemico’s suite of cloud-based solutions serve as trusted resources for the public, government officials, life science, financial and Fortune 500 companies both in the U.S. and internationally. Several products are also directly supported by government entities such as the Food and Drug Administration, Centers for Disease Control and Department of Homeland Security. The company’s work has been nationally recognized by the Smithsonian Institution and the Library of Congress as well as media, including the New York Times, NBC and CNN.
The team at Epidemico, which is a commercial spinoff of Boston Children’s Hospital, Harvard Medical School and the Massachusetts Institute of Technology, has a deep understanding of how to extract value from multiple large data sets and a proven ability to translate that expertise into a rapidly growing business. Likewise, the proprietary software platform is transferrable to multiple industries and business use cases. The combination of Epidemico with Booz Allen’s world class data science capability, and federal and commercial health teams enhances the firm’s collective ability to support a broad set of client needs.
“Being part of Booz Allen Hamilton is very exciting for us,” said Epidemico President and Chief Operating Officer Robin Heffernan. “The teaming works on many levels – overlapping expertise, synergistic product/service mix, and a shared collaborative spirit. This combination will accelerate the development of comprehensive, integrated solutions that will enhance value to clients in both the short and longer-term.”
“This acquisition is perfectly aligned to Booz Allen’s Innovation agenda, adding a creative and successful start-up to our firm,” said Executive Vice President Karen Dahut, who leads the firm’s Strategic Innovation Group. “Their set of successful products, with several popular social media feeds, will also accelerate our efforts to develop alternative revenue streams for Booz Allen.”
Executive Vice President Fred Blackburn, who oversees Booz Allen’s NextGen Analytics Initiative, noted how this acquisition fits “as a critical first step in our broader strategy of growth through organic and inorganic investment – building a full portfolio of analytic platforms and solutions to address the critical need for improved analytics and data science across our client base. We believe that the Health analytics space is the ideal place to begin executing that strategy, given its obvious importance to the population, as well as the associated business opportunities.”
Information about Epidemico is available at http://epidemico.com/
BAHPR-FI
